Health Canada issues revised guidance on interpretation of a significant change to a device
This article was originally published in RAJ Devices
Health Canada has issued revised guidance on the interpretation of a significant change to a class III or IV (medium-high and highest-risk) medical device that would require a manufacture to apply for an amended product licence1,2.
You may also be interested in...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.
An international guideline on managing post approval changes to drugs, which was initially criticized because of its incompatibility with legal frameworks in certain ICH regions such as the EU, has been finalized.